 |
 |
 |
 |
 |
 |
||
 |
 |
 |
 |
 |
| 2 | 1/1 | 返回列表 |
| 查看: 518 | 回復: 1 | |||
| 本帖產(chǎn)生 1 個 翻譯EPI ，點擊這里進行查看 | |||
yaping221木蟲 (正式寫手)
|
[求助]
脂組學類翻譯，謝謝！
|
||
|
In future personalized medicine enabled by lipidomics and metabolomic may expedite the mission of the right patients receiving the right drug at the right time and dose. Recently more potent drugs including monoclonal antibodies able to inhibit proprotein convertase subtilisin/kexin type 9 (PCSK9) and inflammatory pathways have been developed to improve current CAD care. However, these novel targeted treatments seem to be at present too expensive to be widely used among all CAD patients. Thus, sensitive biomarkers are needed for identification of patients most suitable for novel innovative treatments and the metabolomic and lipidomic biomarker candidates, in particular the ceramides, hold the potential to become clinically useful companion diagnostics of the future. |
回復此樓» 猜你喜歡
275求調(diào)劑
已經(jīng)有14人回復
-
調(diào)劑310
已經(jīng)有6人回復
-
283求調(diào)劑
已經(jīng)有3人回復
-
085602 化工專碩 338分 求調(diào)劑
已經(jīng)有12人回復
-
312，生物學求調(diào)劑
已經(jīng)有3人回復
-
化學0703 調(diào)劑 306分 一志愿211
已經(jīng)有4人回復
-
311（085601）求調(diào)劑
已經(jīng)有3人回復
-
復試調(diào)劑
已經(jīng)有3人回復
-
本科雙非材料，跨考一志愿華電085801電氣，283求調(diào)劑，任何專業(yè)都可以
已經(jīng)有6人回復
-
材料與化工272求調(diào)劑
已經(jīng)有9人回復
genhunter
至尊木蟲 (著名寫手)
- 翻譯EPI: 387
- 應助: 259 (大學生)
- 金幣: 9757.4
- 散金: 10
- 紅花: 60
- 帖子: 2484
- 在線: 1793小時
- 蟲號: 2558361
- 注冊: 2013-07-22
- 專業(yè): 腫瘤化學藥物治療
【答案】應助回帖
★ ★ ★ ★ ★ ★ ★ ★ ★ ★ ★ ★ ★ ★ ★ ★ ★ ★ ★ ★ ★ ★ ★ ★ ★ ★ ★ ★ ★ ★
yaping221: 金幣+30, 翻譯EPI+1 2016-03-06 09:30:31
yaping221: 金幣+30, 翻譯EPI+1 2016-03-06 09:30:31
|
In future personalized medicine enabled by lipidomics and metabolomic may expedite the mission of the right patients receiving the right drug at the right time and dose. Recently more potent drugs including monoclonal antibodies able to inhibit proprotein convertase subtilisin/kexin type 9 (PCSK9) and inflammatory pathways have been developed to improve current CAD care. 在未來基于脂類組學和代謝組學的個性化醫(yī)學可以加快對合適病人的選擇，以及選對藥物，用藥時間和劑量的決定。最近, 更為有效的藥物，包括能抑制前蛋白轉(zhuǎn)化酶枯草溶菌素 9型（PCSK9）和炎癥通路的單克隆抗體已經(jīng)開發(fā)，用于改善冠狀動脈疾病的治療。 However, these novel targeted treatments seem to be at present too expensive to be widely used among all CAD patients. Thus, sensitive biomarkers are needed for identification of patients most suitable for novel innovative treatments and the metabolomic and lipidomic biomarker candidates, in particular the ceramides, hold the potential to become clinically useful companion diagnostics of the future. 然而，在目前看來，這些新的靶向治療比較昂貴，難以在所有冠狀動脈疾病患者中廣泛應用。因此，需要用靈敏的生物標志物去確定最合適新療法以代謝和脂類生物標志物測定的的候選患者, 尤其是神經(jīng)酰胺，未來有可能成為臨床上有用的輔助診斷。 |
2樓2016-03-05 15:38:03
相關版塊跳轉(zhuǎn)
我要訂閱樓主 yaping221 的主題更新
| 2 | 1/1 | 返回列表 |
| 最具人氣熱帖推薦 [查看全部] | 作者 | 回/看 | 最后發(fā)表 | |
|---|---|---|---|---|
|
[考研] 本科雙非材料，跨考一志愿華電085801電氣，283求調(diào)劑，任何專業(yè)都可以 +5 | 芝士雪baoo 2026-03-28 | 6/300 |
|
|---|---|---|---|---|
|
|
[考研] 347求調(diào)劑 +3 | 山頂見α 2026-03-25 | 3/150 |
|
|
|
[考研] 304求調(diào)劑 +6 | 曼殊2266 2026-03-27 | 6/300 |
|
|
|
[考研] 321求調(diào)劑 +6 | 材料cailiao 2026-03-21 | 6/300 |
|
|
|
[考研] 339求調(diào)劑 +6 | 烤麥芽 2026-03-27 | 8/400 |
|
|
|
[考研] 0703化學/290求調(diào)劑/本科經(jīng)歷豐富/工科也可 +9 | 丹青奶蓋 2026-03-26 | 10/500 |
|
|
[考研] 材料求調(diào)劑 一志愿哈工大總分298分，前三科223分 +5 | dongfang59 2026-03-27 | 5/250 |
|
|
|
[考研] 一志愿211院校 344分 東北農(nóng)業(yè)大學生物學學碩，求調(diào)劑 +5 | 丶風雪夜歸人丶 2026-03-26 | 8/400 |
|
|
|
[考研] 307求調(diào)劑 +8 | 超級伊昂大王 2026-03-24 | 9/450 |
|
|
|
[考研] 315調(diào)劑 +4 | 0860求調(diào)劑 2026-03-26 | 5/250 |
|
|
|
[考研] 調(diào)劑推薦 +5 | 清酒714 2026-03-26 | 6/300 |
|
|
|
[考研] 材料學碩333求調(diào)劑 +8 | 北道巷 2026-03-24 | 8/400 |
|
|
|
[考研] 一志愿陜師大生物學071000，298分，求調(diào)劑 +5 | SYA！ 2026-03-23 | 5/250 |
|
|
|
[考研] 316求調(diào)劑 +5 | 江辭666 2026-03-26 | 5/250 |
|
|
|
[考研] 342求調(diào)劑 +3 | 加油a李zs 2026-03-26 | 3/150 |
|
|
|
[考研] 309求調(diào)劑 +4 | gajsj 2026-03-25 | 5/250 |
|
|
|
[考研] 考研調(diào)劑 +6 | 來好運來來來 2026-03-21 | 7/350 |
|
|
|
[考研] 292求調(diào)劑 +4 | 鵝鵝鵝額額額額?/a> 2026-03-24 | 4/200 |
|
|
|
[考研] 一志愿國科過程所081700，274求調(diào)劑 +3 | 三水研0水立方 2026-03-23 | 3/150 |
|
|
|
[考研] 求調(diào)劑院校信息 +6 | CX 330 2026-03-21 | 6/300 |
|